Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
78 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05382559 | A Study of ASP3082 in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 681 | Astellas Pharma IncINDUSTRY | 7 | Sep 30, 2026 | clinicaltrials |
| NCT03182244 | A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation | completed | Phase 3 | 276 | Astellas Pharma IncINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT06364696 | A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | terminated | Phase 1 | 60 | Astellas Pharma IncINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03641560 | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 4 | 52 | Astellas Pharma IncINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT01186861 | Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | completed | Phase 2 | 205 | Astellas Pharma IncINDUSTRY | 9 | Nov 18, 2025 | clinicaltrials |
| NCT01221077 | Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | completed | Phase 2 | 88 | Astellas Pharma IncINDUSTRY | 6 | Nov 18, 2025 | clinicaltrials |
| NCT02294461 | An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants | completed | Phase 3 | 395 | Astellas Pharma IncINDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT02310321 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | completed | Phase 1 / Phase 2 | 97 | Astellas Pharma IncINDUSTRY | 3 | Sep 2, 2025 | clinicaltrials |
| NCT02918968 | Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | completed | Phase 4 | 206 | Astellas Pharma IncINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01288911 | A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | completed | Phase 2 | 375 | Astellas Pharma IncINDUSTRY | 8 | Dec 6, 2024 | clinicaltrials |
| NCT01534052 | A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | completed | Phase 2 | 52 | Astellas Pharma IncINDUSTRY | 3 | Dec 6, 2024 | clinicaltrials |
| NCT03528629 | A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | completed | N/A | 18 | Astellas Pharma IncINDUSTRY | 1 | Dec 2, 2024 | clinicaltrials |
| NCT01284920 | A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 47 | Astellas Pharma IncINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02669771 | Long-Term Specified Drug Use-Results Survey for Xtandi Capsule | completed | — | 1,018 | Astellas Pharma IncINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT00514007 | Study of Continuous OSI-906 Dosing | completed | Phase 1 | 95 | Astellas Pharma IncINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT00514306 | Study of Intermittent OSI-906 Dosing | completed | Phase 1 | 79 | Astellas Pharma IncINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT00739453 | A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) | completed | Phase 1 | 95 | Astellas Pharma IncINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT00924989 | A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma(GALACCTIC) | completed | Phase 3 | 139 | Astellas Pharma IncINDUSTRY | 9 | Nov 20, 2024 | clinicaltrials |
| NCT01101906 | A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC | terminated | Phase 2 | 23 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT02500927 | A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations | terminated | Phase 2 | 31 | Astellas Pharma IncINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05457842 | A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery | terminated | Phase 2 | 1 | Astellas Pharma IncINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02192697 | An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | terminated | Phase 1 / Phase 2 | 124 | Astellas Pharma IncINDUSTRY | 3 | Nov 14, 2024 | clinicaltrials |
| NCT03945253 | Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 6 | Astellas Pharma IncINDUSTRY | 1 | Nov 13, 2024 | clinicaltrials |
| NCT02181660 | Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 24 | Astellas Pharma IncINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT04094506 | Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 9 | Astellas Pharma IncINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT01261572 | Study to Find Maintenance Dose for Periodic Administration of ASP3550 | completed | Phase 2 | 155 | Astellas Pharma IncINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT01964170 | A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer | completed | Phase 3 | 234 | Astellas Pharma IncINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT02038673 | An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors | completed | Phase 1 | 86 | Astellas Pharma IncINDUSTRY | 4 | Oct 31, 2024 | clinicaltrials |
| NCT00285259 | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | completed | Phase 2 | 112 | Astellas Pharma IncINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT03070990 | A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma | completed | Phase 1 | 19 | Astellas Pharma IncINDUSTRY | 1 | Oct 18, 2024 | clinicaltrials |
| NCT03219333 | A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer(EV-201) | completed | Phase 2 | 219 | Astellas Pharma IncINDUSTRY | 8 | Aug 27, 2024 | clinicaltrials |
| NCT01409135 | A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4 | completed | Phase 1 | 34 | Astellas Pharma IncINDUSTRY | 2 | Mar 12, 2024 | clinicaltrials |
| NCT01302041 | A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy | completed | Phase 2 | 67 | Astellas Pharma IncINDUSTRY | 4 | Oct 2, 2018 | clinicaltrials |
| NCT01284192 | Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma) | completed | Phase 1 | 46 | Astellas Pharma IncINDUSTRY | 1 | Jun 28, 2016 | clinicaltrials |
| NCT01325571 | A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis | completed | Phase 3 | 83 | Astellas Pharma IncINDUSTRY | 1 | Mar 9, 2016 | clinicaltrials |
| NCT01007292 | A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment | completed | Phase 2 | 43 | Astellas Pharma IncINDUSTRY | 4 | Oct 19, 2015 | clinicaltrials |
| NCT00902291 | A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer | completed | Phase 2 | 205 | Astellas Pharma IncINDUSTRY | 5 | Sep 14, 2015 | clinicaltrials |
| NCT00498914 | Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects | terminated | Phase 2 | 41 | Astellas Pharma IncINDUSTRY | 4 | Sep 4, 2015 | clinicaltrials |
| NCT00818480 | An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 | completed | Phase 2 | 10 | Astellas Pharma IncINDUSTRY | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01009775 | A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma | completed | Phase 2 | 64 | Astellas Pharma IncINDUSTRY | 2 | Sep 4, 2015 | clinicaltrials |
| NCT00514267 | An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | completed | Phase 1 / Phase 2 | 32 | Astellas Pharma IncINDUSTRY | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00568516 | Phase II Study of ASP3550 in Patients With Prostate Cancer | completed | Phase 2 | 273 | Astellas Pharma IncINDUSTRY | 1 | Oct 29, 2014 | clinicaltrials |
| NCT00309088 | FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients | completed | Phase 3 | 80 | Astellas Pharma IncINDUSTRY | 1 | Aug 25, 2014 | clinicaltrials |
| NCT01401504 | Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors | completed | Phase 1 | 29 | Astellas Pharma IncINDUSTRY | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00378690 | A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD(ICELAND) | completed | Phase 3 | 706 | Astellas Pharma IncINDUSTRY | 10 | Jun 4, 2014 | clinicaltrials |
| NCT00519233 | AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer | completed | Phase 1 | 13 | Astellas Pharma IncINDUSTRY | 1 | May 2, 2014 | clinicaltrials |
| NCT00410514 | A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) | completed | Phase 2 | 200 | Astellas Pharma IncINDUSTRY | 2 | Apr 4, 2014 | clinicaltrials |
| NCT01352208 | Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients | terminated | Phase 1 / Phase 2 | 13 | Astellas Pharma IncINDUSTRY | 3 | Mar 24, 2014 | clinicaltrials |
Data updated 13 hours agoSource updated unknownsource: clinicaltrials